Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

There are no studies available for the assessment of the oral, inhalation and dermal acute toxicity for the target substance D-(-)-lactic acid. Therefore, data available from the suitable read-across substance L(+)-lactic acid was used to assess the acute toxicity via the standard routes of administration (oral, inhalation, dermal). In all studies, the obtained LD50 or LC50 values for the oral, dermal or inhalation route are above the limit values of the relevant OECD guidelines. Thus, no classification for acute toxicity is warranted. For details and justification of read-across please refer to the report attached in section 13 of IUCLID.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Referenceopen allclose all

Endpoint:
acute toxicity: oral
Type of information:
read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
supporting study
Justification for type of information:
For details and justification of read-across please refer to the read-across report attached to IUCLID section 13.
Reason / purpose for cross-reference:
read-across source
Sex:
male
Dose descriptor:
LD50
Effect level:
> 5 000 mg/kg bw
Based on:
test mat.
Remarks on result:
other: 1 out of 5 males died
Sex:
female
Dose descriptor:
LD100
Effect level:
< 5 000 mg/kg bw
Based on:
test mat.
Remarks on result:
other: All females died
Mortality:
Four males survived the 14-day duration of the study. One male and all 5 females were found dead at 1 to 2 or 3 to 4 hours after dosing (2 females), in the morning of day 1 (one male and 2 females), and in the morning of day 10 (one female).
Clinical signs:
other: All individuals showed signs of adverse effects.
Gross pathology:
Gross necropsy of one male and 5 females found dead on days 0, 1, or 10 revealed diffuse or multiple, focal, black or black- brown discolorations of the glandular stomach; and dark contents in the stomachs of 4 of these 6 animals. Also observed during necropsy of 2 females found dead on day 0 or day 10 were: a diffuse, grey-green discoloration of the lung and a diffuse, grey-black discoloration of the trachea for the female found dead
on day 0; and diffuse, tan adhesion of the liver to the stomach (serosa) and diffuse, severe dilation (with food material) of the stomach for the female found dead on day 10. Necropsy of 2 surviving males revealed: a solitary depression on one kidney and multiple, red discolorations on the lung of one male; and diffuse, moderate dilation of the stomach, mucosal sloughing of the non-glandular stomach, a solitary, yellow-white discoloration on the liver, and multiple adhesions between the liver and stomach of the second surviving male.
No other abnormalities were observed during necropsy of all animals.

Four males survived the 14-day duration of the study. One male and all females were found dead on the day of dosing, on  day 1 or on day 10. For male rats the LD50 was > 5000 mg/kg bw. For female rats the LD50 was < 5000 mg/kg bw.

Interpretation of results:
study cannot be used for classification
Conclusions:
Based on the results and in accordance with EPA OPP-81-1 guideline, the LD50 values of the test article were determined to be higher to 5000 mg/kg bw for males and lower to 5000 mg/kg bw for females.
Executive summary:

L(+)-lactic acid was administered by oral gavage to 5 male and 5 female albino rats at a dose level of 5 grams per kilogram of body weight to evaluate the acute oral toxic potential. This study was designed to comply with procedures described in the EPA/OPP Guidelines, 1982. Four males survived the 14-day duration of the study. One male and all females were found dead on the day of dosing (day 0), on day l, or on day 10. Body weight gains were observed for 3 surviving males, and a small weight loss was observed for the fourth surviving male. Body weight losses were observed for all other animals that were found dead. Lethargy and salivation were observed for all animals, and crusty muzzle was observed for 9 animals on the day of dosing and as late as day 9 for one female. Other abnormal clinical signs observed for some animals on the day of dosing and as late as day 2 included ataxia, prostration, irregular breathing, noisy breathing, squinting, lacrimation, crusty eyes, crusty nose, and body cool to touch» Other abnormal clinical signs observed prior to death of one female on day 10 included yellow/brown stained fur in the perianal region, abdomen swollen, no stools, and few stools. No other abnormal clinical signs were observed during the study. Necropsy of the 6 found dead animals revealed black discolorations of the glandular stomach, and dark contents in the stomachs of 4 of these animals. Grey-green discoloration of the lung and grey-black discoloration of the trachea were also observed during necropsy of one female found dead on day 0, and liver to stomach adhesions and severe dilation of the stomach (with food material) were also observed during necropsy of the female found dead on day 10. Necropsy of 2 surviving males revealed: a depression on one kidney and red discolorations on the lung of one animal; and dilation of the stomach, mucosal sloughing of the stomach, a yellow-white discoloration on the liver, and liver to stomach adhesions for one animal. No other abnormalities were observed during necropsy of all animals after death or after sacrifice on day 14. Based on the results and in accordance with EPA OPP-81-1 guideline, the LD50 values of the test article were determined to be higher to 5000 mg/kg bw for males and lower to 5000 mg/kg bw for females.

This information is used in a read-across approach in the assessment of the target substance. For details and justification of read-across please refer to the read-across report attached to IUCLID section 13.

Endpoint:
acute toxicity: oral
Type of information:
read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Justification for type of information:
For details and justification of read-across please refer to the read-across report attached to IUCLID section 13.
Reason / purpose for cross-reference:
read-across source
Sex:
female
Dose descriptor:
LD50
Effect level:
3 543 mg/kg bw
Based on:
test mat.
95% CL:
9.7
Sex:
male
Dose descriptor:
LD50
Effect level:
4 936 mg/kg bw
Based on:
test mat.
95% CL:
10.8
Mortality:
All main study mortalities and range-finding mortalities (6,310 mg/kg bw) occurred after dosing on day 0 or in the morning of day 1 except for one main study female dosed at 3162 mg/kg bw that was found dead in the morning of day 2. Range-finding animals dosed at 1,000, 1,585, 2,512, and 3,981 mg/kg bw and surviving main study animals were sacrificed after 14-day observation periods.
For individual results, see Table 1 in "Any other information on results incl. tables".
Clinical signs:
other: Lethargy, ataxia, prostration, irregular breathing, piloerection, squinting, lacrimation, salivation, crusty eyes and muzzle, loose stools, damp or yellow/brown stained fur, and moribund were abnormal clinical signs observed for main study animals as earl
Gross pathology:
Abnormal necropsy findings were observed for all found dead main study animals, and for the 4 surviving main study females dosed at 3,162 mg/kg bw. Abnormalities observed during necropsy of found dead animals included: discolored lungs; firm texture of lungs; green foci on one lung; erosion of stomachs; dark, black, brown, and/or fluid contents of stomachs; black and/or brown discolored stomachs; a distended stomach with white mucosa; mucosal sloughing, ulceration, and hemorrhage of stomachs; discolored livers; white foei on livers; pale capsular areas, superficial erosion, or mottled livers; a discolored diaphragm; green-black or brown-black discolored kidneys; and red-brown exudate in the nasal and/or oral regions. Mottled lungs were observed during necropsy of 3 surviving animals dosed at 3162 mg/kg bw, and thickened stomachs were also observed during necropsy of 2 surviving animals of the same group. No other abnormalities were observed during necropsy of all main study animals.

Table 1: Individual mortalities

Main Study Dose Level (mg/kg bw)
Number dead/number tested
3162 3548 3981 4467 5012 5623 6310
Males -- -- -- 1/5 3/5 4/5 5/5
Females 1/5 2/5 5/5 5/5 5/5 5/5 5/5

-- = None tested

Interpretation of results:
other: CLP criteria not met
Conclusions:
The oral LD50 value in rats after treatment with L(+)-lactic acid was determined to be 3543 mg/kg bw for females and 4936 mg/kg bw for males.
Executive summary:

In an acute oral toxicity study according to EPA OPP81-1, groups of young Albino rats (5/sex/dose) were given single oral doses of L(+)-lactic acid in water of 3162, 3548, 3981, 4467, 5012, 5623, 6310 mg/kg bw and were observed for 14 days. Mortality occured after dosing on day 0 or in the morning of day 1 except for one main study female dosed at 3162 mg/kg that was found dead in the morning of day 2. Mortality occured in a dose-dependent manner. At the highest dose, no animal survived. Abnormal clinical signs were observed 0 to 1 hour after dosing and day 2. Abnormal necropsy findings were observed for all found dead main study animals, and for the 4 surviving main study females dosed at 3162 mg/kg bw. Based on the results from this study, an oral LD50 in rats was determined to be 3543 mg/kg bw for females and 4936 mg/kg bw for males using the methodology described in the EPA/OPP Guidelines 1982.

L(+)-lactic acid does not need to be classified according to GHS criteria.

This acute oral study is classified as acceptable. It does satisfy the guideline requirement for an acute oral study (EPA OPP 81-1) in the rats.

This information is used in a read-across approach in the assessment of the target substance. For details and justification of read-across please refer to the read-across report attached to IUCLID section 13.

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LD50
Value:
3 543 mg/kg bw
Quality of whole database:
Guideline study

Acute toxicity: via inhalation route

Link to relevant study records
Reference
Endpoint:
acute toxicity: inhalation
Type of information:
read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Justification for type of information:
For details and justification of read-across please refer to the read-across report attached to IUCLID section 13.
Reason / purpose for cross-reference:
read-across source
Duration of exposure:
h
Sex:
male/female
Dose descriptor:
LC50
Effect level:
> 7.94 mg/L air
Based on:
test mat.
Exp. duration:
4 h
Mortality:
1 female died.
Clinical signs:
other: Please refer to box "Any other information on results incl. tables".
Body weight:
At the beginning of the study, mean body weicihts for individual groups were within 20% of the overall mean for each sex. All groups of male rats gained weight within the first week after exposure in comparison to pre-exposure weights (3% for sham-exposed, 2< for L(+)-lactic acid,respectively). Female rats in the sham group gained weight during the first week after exposure (less than 1%). Female rats in the treated group lost weight during the first week after exposure (7%). After 14 days, all surviving animals had gained weight in comparison to pre-exposure weights (14% for males, 7% for females). No significant differences were observed in body weight between treated and control groups.
Gross pathology:
All surviving animals were necropsied at the termination of the study. The animal that died during the study was necropsied immediately. No gross lesions were observed at necropsy.

Clinical signs:

Rapid breathing and eye tearing were observed during exposure. At one and three hours after exposure, all animals (including the sham controls) had a hunched posture, ruffled and ungroomed fur, brown stained fur and red-stained fur surrounding the eyes (tearing). By 24 hours, female treated rats had ruffled and stained coats. All other animals appeared normal at 24 hours and for the remainder of the 14 day observation period. Several treated female rats continued to have ruffled fur up to 4 days after exposure.

Mass Median Diameter:

The Mass Median Diameters ranged from 2.03 to 2.14 microns and averaged 2.09.

Interpretation of results:
other: CLP criteria not met
Conclusions:
Based on these results, the LC50 of L(+)-lactic acid is greater than 7.94 mg/L.


Executive summary:

In an acute inhalation toxicity study according to OECD 403, groups of young adult F344 rats (5/sex/dose) were exposed by inhalation route to L(+)-lactic acid in a concentration of approximately 7.94 mg/L for 4 hours.

Rapid breathing and eye tearing were observed during exposure. At one and three hours after exposure, all animals (including the sham controls) had a hunched posture, ruffled and ungroomed fur, brown stained fur and red-stained fur surrounding the eyes (tearing). After 24 hours, female treated rats had ruffled and stained coats. All other animals appeared normal at 24 hours and for the remainder of the 14 day observation period. Several treated female rats continued to have ruffled fur up to 4 days after exposure. One female rat from the treated group died on day 9. All other animals survived until the end of the study. At gross pathology no adverse lesions were observed.

Based on these results, the LC50 of L(+)-lactic acid is greater than 7.94 mg/L. This acute inhalation study is classified as acceptable. It does satisfy the guideline requirement for an acute inhaltion study (OECD TG 403) in rats.

This information is used in a read-across approach in the assessment of the target substance. For details and justification of read-across please refer to the read-across report attached to IUCLID section 13

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LC50
Value:
> 7.94 mg/L air
Physical form:
inhalation: aerosol
Quality of whole database:
Guideline study

Acute toxicity: via dermal route

Link to relevant study records
Reference
Endpoint:
acute toxicity: dermal
Type of information:
read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Justification for type of information:
For details and justification of read-across please refer to the read-across report attached to IUCLID section 13.
Reason / purpose for cross-reference:
read-across source
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Mortality:
All animals survived the 14-day duration of the study.
Clinical signs:
other: No abnormal clinical signs were observed during the study.
Gross pathology:
Brown, crusted, and raised discolorations of the treated skin were observed during necropsy of 3 males and 3 females. Multiple depressions in the treated skin were observed during necropsy of one of the same males, of 2 other males, and of one other female. A dark red focus was also observed on the lung of one male. No other abnormalities were observed during necropsy of all males and 4 females, and no abnormalities were observed during necropsy of one female.

Skin reactions:

Severe erythema and severe edema were observed for all animals after test article removal on day 1. Erythema decreased in severity (to well defined or very slight) for 2 males on day 14 and for one female on day 12. Edema decreased in severity (to moderate, slight, or very slight) for all males and 3 females as early as day 2. No erythema was observed on day 14, and no edema was observed on days 12 to 14 for one female. Also, no edema was observed on day 14 for one male. Other dermal reactions observed at test sites included:

- Blanching: all animals on day l and as late as days 2, 3, or 4 for 6 animals.

- Necrosis (brown-green discoloration): all animals on days l and 2, as late as days 3, 5, or 6 for 3 males, and to day 11 for 4 females.

- Eschar formation: all animals on days 2 to 11, and for 7 animals to day 14. Eschar was present along the abrasion lines only of one female on days 7 to 11.

- Eschar peeled off: one female on day 12, and 2 males on day 14.

- Atonia: all males and 3 females from days 3 or 4 to days 11 or 14.

- Desquamation: all animals from days 10 or 11 to day 14.

- Fissures: one male and 4 females as early as day 5 and as late as day 14.

- Denuded areas along abrasion lines: one female on day 14. No other dermal reactions were observed during the study.

Interpretation of results:
other: CLP criteria not met
Conclusions:
L(+)-lactic acid is not dermally toxic and the LD50 is >2000 mg/kg bw.
Executive summary:

In an acute dermal toxicity study conducted according to EPA OPP 81-2, young adult New Zealand White rabbits (5/sex) were dermally exposed to L(+)-lactic acid for 24 hours to 10% of the body surface area at a dose of 2000 mg/kg bw. Animals then were observed for 14 days.

All animals survived the 14-day duration of the study and gained body weight. No abnormal clinical signs were observed during the study. Severe erythema and severe edema were observed at the test sites of all animals after removal on day 1. Other dermal reactions observed at test sites included: Blanching, necrosis, eschar formation, eschar along abrasion lines, eschar peeled off, atonia, desquamation, fissures and denuded areas along abrasion lines. No other dermal reactions were observed during the study. Based on the results the dermal LD50 is > 2000 mg/kg bw. This acute dermal study is classified as acceptable. It does satisfy the guideline requirement for an acute dermal study (EPA OPP 81 -2) in the rabbits.

This information is used in a read-across approach in the assessment of the target substance. For details and justification of read-across please refer to the read-across report attached to IUCLID section 13.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
> 2 000 mg/kg bw
Quality of whole database:
Guideline study

Additional information

There are no studies available for the assessment of the acute oral, inhalation and dermal toxicity for the target substance D-(-)-lactic acid. Therefore, data available from the suitable read-across substance L(+)-lactic acid was used to assess the acute toxicity via the standard routes of administration (oral, inhalation, dermal)

In an acute oral toxicity study according to EPA OPP81-1, groups of young Albino rats (5/sex/dose) were given single oral doses of L(+)-lactic acid in water of 3162, 3548, 3981, 4467, 5012, 5623, 6310 mg/kg bw and were observed for 14 days. Mortality occurred after dosing mainly on day 0 or in the morning of day 1 in a dose-dependent manner. At the highest dose, no animal survived. The LD50 was determined to be 3543 mg/kg bw for females and 4936 mg/kg bw for males.

In an acute inhalation toxicity study conducted according to OECD 403, groups of young adult F344 rats (5/sex/dose) were exposed by inhalation to L(+)-lactic acid at a concentration of approximately 7.94 mg/L for 4 hours. One female rat from the treated group died on day 9. All other animals survived until the end of the study. Based on these results, the LC50 of L(+)-lactic acid is greater than 7.94 mg/L.

In an acute dermal toxicity study conducted according to EPA OPP 81-2, young adult New Zealand White rabbits (5/sex) were dermally exposed to L(+)-lactic acid for 24 hours via 10% of the body surface area at a dose of 2000 mg/kg bw. Animals were then observed for 14 days. All animals survived the 14-day duration of the study and gained body weight. No abnormal clinical signs were observed during the study. Severe erythema and oedema were observed at the test sites of all animals after removal on day 1. The dermal LD50 is > 2000 mg/kg bw.

Based on the available data from the source substance L(+)-lactic acid, and as in all studies the LD50 or LC50 values for the oral, dermal or inhalation route are above the limit values of the relevant OECD guideline, no classification for acute toxicity is warranted for the target substance lactic acid. For details and justification of read-across please refer to the report attached in section 13 of IUCLID.

Justification for classification or non-classification

Based on the available data, the target substance D-(-)-lactic acid does not warrant classification for acute toxicity in accordance with CLP Regulation 1272/2008.